Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATShares Issued
Ratios

Forte Biosciences (FBRX) EBIAT (2016 - 2020)

Forte Biosciences (FBRX) has disclosed EBIAT for 5 consecutive years, with -$4.6 million as the latest value for Q4 2020.

  • Quarterly EBIAT rose 56.76% to -$4.6 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was -$46.5 million through Dec 2020, down 255.19% year-over-year, with the annual reading at -$69.4 million for FY2025, 95.54% down from the prior year.
  • EBIAT for Q4 2020 was -$4.6 million at Forte Biosciences, up from -$5.1 million in the prior quarter.
  • The five-year high for EBIAT was -$383000.0 in Q3 2018, with the low at -$34.8 million in Q2 2020.
  • Average EBIAT over 5 years is -$9.0 million, with a median of -$8.7 million recorded in 2016.
  • The sharpest move saw EBIAT skyrocketed 96.15% in 2018, then tumbled 5417.62% in 2020.
  • Over 5 years, EBIAT stood at -$8.4 million in 2016, then dropped by 28.55% to -$10.8 million in 2017, then tumbled by 80.89% to -$19.6 million in 2018, then soared by 46.01% to -$10.6 million in 2019, then skyrocketed by 56.76% to -$4.6 million in 2020.
  • According to Business Quant data, EBIAT over the past three periods came in at -$4.6 million, -$5.1 million, and -$34.8 million for Q4 2020, Q3 2020, and Q2 2020 respectively.